Form 4: NeuroPace Director Uri Geiger Acquires Shares

NeuroPace Inc. Director Uri Geiger acquired 913 shares of common stock at $13 per share as part of his non-employee director compensation.

Summary

• Uri Geiger, a Director and 10% owner of NeuroPace Inc. (NPCE), acquired 913 shares of common stock.
• The transaction occurred on March 20, 2026, at a price of $13 per share.
• These shares were issued pursuant to the Issuer's non-employee director compensation policy, in lieu of quarterly retainer fees.
• Following this transaction, Uri Geiger directly owns 14,858 shares of common stock.
• Additionally, 4,432,948 shares are indirectly beneficially owned through Accelmed Partners II LP, where Uri Geiger is the managing partner of the general partner and holds sole voting and dispositive power.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director increasing their stake, even through compensation, generally indicates confidence in the company's trajectory and aligns management interests with shareholders.

Positives

• Director Uri Geiger increased his direct ownership in NeuroPace Inc. by acquiring 913 shares.
• The acquisition was part of a compensation policy, indicating alignment of director interests with shareholders.

Industry Context

StockSavvy.ai notes that insider purchases, even those related to compensation, can signal confidence from company leadership in the firm's future prospects, aligning director interests with long-term shareholder value. This is a routine disclosure for director compensation.

Related Party Transactions

• Uri Geiger, a Director, indirectly beneficially owns 4,432,948 shares through Accelmed Partners II LP, where he is the managing partner of the general partner and has sole voting and dispositive power.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholder value due to increased personal stake.

Key Dates

Recommendation

The acquisition of shares by a director, even as part of compensation, is a positive signal indicating management's continued confidence and alignment with shareholder interests. However, this single transaction, while positive, is not substantial enough on its own to warrant a 'buy' recommendation without further fundamental analysis of NeuroPace Inc.'s overall financial health and market position. Therefore, a 'hold' recommendation is appropriate, acknowledging the positive insider action while awaiting broader performance indicators.

Keywords

NeuroPace, NPCE, Uri Geiger, Insider Trading, Form 4, Stock Acquisition, Director Compensation, Beneficial Ownership, Accelmed Partners